Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 4/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.41 |
| ▸ | OXTR | P30559 | 1/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16495220 | 0.86 | MAPT (0.46) | MAPTACHETNFALOX5EPHX2 | |
| SCHEMBL16495164 | 0.85 | HDAC1 (0.44) | MAPTACHETNFALOX5EPHX2 | |
| SCHEMBL16495305 | 0.84 | TNF (0.48) | MAPTACHETNFALOX5EPHX2 | |
| SCHEMBL16495315 | 0.82 | PRMT1 (0.48) | MAPTTP53SMN1; SMN2ACHETNF | |
| SCHEMBL16495254 | 0.81 | MEN1 (0.42) | MAPTACHETNFALOX5EPHX2 | |
| SCHEMBL16495298 | 0.80 | ACHE (0.40) | MAPTTP53SMN1; SMN2ACHEPOLB | |
| SCHEMBL16495163 | 0.78 | TNF (0.43) | MAPTTP53SMN1; SMN2ACHETNF | |
| SCHEMBL27429810 | 0.76 | TNF (0.45) | ACHETNFALOX5EPHX2EGFR | |
| SCHEMBL16495267 | 0.76 | MAPT (0.47) | MAPTTNFALOX5EPHX2 | |
| SCHEMBL16495182 | 0.76 | ACHE (0.58) | MAPTTP53SMN1; SMN2ACHEALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294850-A1 | INDOLINE DERIVATIVES | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294850-A1 | INDOLINE DERIVATIVES | BCHE, ACHE, INMT | MAPT 2067/4885TP53 4595/4885SMN1; SMN2 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.